相关实验视频
Updated: Jun 10, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
[中风部门的血糖管理及其与发病率和死亡率的关系]
A Ruiz-Hernández1, E González-Arnaiz1, I González-Puente1
1Complejo Asistencial Universitario de León, 24001 León, España.
Revista de neurologia
|October 15, 2024
概括
在中风后患有高血糖症 (葡萄糖水平≥155 mg/dL) 的患者经历了更高的血糖变化,并发症和死亡率. 胰岛素治疗的类型 (静脉注射与皮下注射) 并没有影响结果.
科学领域:
- 神经学 神经学
- 内分泌学 在内分泌学.
- 临床医学 临床医学
背景情况:
- 高血糖在中风患者中很常见,并与不良结果相关.
- 在中风病组中高血糖的有效管理对于患者的康复至关重要.
- 血糖控制策略旨在减少并发症和死亡率.
研究的目的:
- 评估中风单位的高血糖治疗方案.
- 为了比较静脉注射 (IV) 和皮下 (SC) 胰岛素治疗高血糖症 (≥155 mg/dL) 的发病率和死亡率.
主要方法:
- 一项针对181名中风病人的前性观察性研究 (2022年7月至10月).
- 收集的人口,血糖和预后数据.
- 评估血糖变异性 (葡萄糖的SD),急性并发症和出院时的死亡率和3个月.
- 根据胰岛素治疗方案 (IV vs. SC) 和高血糖类型 (2 型糖尿病与压力高血糖) 分析了子组.
主要成果:
- 25.4%的患者需要胰岛素进行血糖≥155 mg/dL (18 IV, 28 SC).
- 需要胰岛素的患者表现出更高的血糖变化 (33.3 vs 11.7 mg/dL) 和急性并发症 (43.5% vs 19.2%).
- 胰岛素组3个月死亡率较高 (19.5%对6.6%).
结论:
- 在中风患者中,高血糖 (≥155 mg/dL) 与血糖变异性,并发症和死亡率的增加有关.
- 在IV和SC胰岛素疗法之间没有观察到结果的显著差异.
- 这些发现强调了在中风患者中管理高血糖的重要性,无论胰岛素的输送方法如何.
相关概念视频
Diabetes: Management and Pharmacotherapy
238
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
238
Atherosclerosis IV: Nursing Management
2
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
2
Hypoglycemia and Glucagon
164
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
164
Acute Coronary Syndrome IV: Interprofessional Care
3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Angina IV: Management
3
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
3

